GlassScriptPhysician profile
Sarah Dunn Trezza
NPI 1447525118
$2,250.52
in general payments reported to CMS, 2019-2025
23 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $638 · 2023: $515 · 2024: $483 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $579.43 | 2022-2025 | Azstarys |
| Tris Pharma INC | $514.62 | 2021-2025 | Onyda Xr, Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $188.67 | 2023-2025 | Qelbree, Qelbree |
| Alk-Abello, INC | $135.92 | 2023-2025 | Grastek, Odactra, Neffy |
| Ironshore Pharmaceuticals INC. | $105.01 | 2022-2024 | Jornay Pm |
| Pfizer INC. | $95.55 | 2021-2025 | |
| Sobi, INC | $80.42 | 2021-2023 | |
| Kaleo, INC. | $74.71 | 2022-2024 | Auvi-Q |
| Collegium Pharmaceutical, INC. | $68.73 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $62.27 | 2021-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $54.70 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $51.53 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $37.78 | 2023-2024 | Flumist Quadrivalent |
| Seqirus USA INC | $31.31 | 2022-2025 | Flucelvax |
| Adlon Therapeutics L.P. | $25.65 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $25.00 | 2025 | Neffy |
| Genentech USA, INC. | $20.28 | 2021 | |
| Sanofi Pasteur INC. | $19.58 | 2021 | |
| Verrica Pharmaceuticals INC. | $19.40 | 2025 | Ycanth |
| Cranial Technologies, INC | $16.47 | 2023 | Doc Band |
| Phadia US INC. | $16.44 | 2021 | |
| Neos Therapeutics, LP | $13.69 | 2024 | Adzenys Xr-Odt |
| Cognoa, INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Trezza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.